Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
The company's revenues were up, but fell short of Wall Street estimates as growth in the European market was hampered by lower sales to pharma customers there.
Waters said the acquisition is part of a strategy to develop simpler, more streamlined mass spec workflows that will be accessible to non-expert users.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.
In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.
